Journal
ACS CHEMICAL BIOLOGY
Volume 14, Issue 5, Pages 994-1001Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschembio.9b00173
Keywords
-
Categories
Funding
- National Cancer Institute of the National Institutes of Health [P30CA016042]
- Jonsson Cancer Center Foundation seed grant
- V Foundation for Cancer Research V Scholar Award
- Research Corporation for Science Advancement Cottrell Scholar Award
- University of California Cancer Research Coordinating Committee Funds
- Ruth L. Kirschstein National Research Service Award [GM007185]
- UCLA Molecular Biology Institute Whitcome Fellowship
Ask authors/readers for more resources
Targeting the leukemia proliferation cycle has been a successful approach to developing antileukemic therapies. However, drug screening efforts to identify novel antileukemic agents have been hampered by the lack of a suitable high-throughput screening platform for suspension cells that does not rely on flow-cytometry analyses. We report the development of a novel leukemia cell-based high throughput chemical screening platform for the discovery of cell cycle phase specific inhibitors that utilizes chemical cell cycle profiling. We have used this approach to analyze the cell cycle response of acute lymphoblastic leukemia CCRF-CEM cells to each of 181420 druglike compounds. This approach yielded cell cycle phase specific inhibitors of leukemia cell proliferation. Further analyses of the top G2-phase and M-phase inhibitors identified the leukemia specific inhibitor 1 (Leusin-1). Leusin-1 arrests cells in G2 phase and triggers an apoptotic cell death. Most importantly, Leusin-1 was more active in acute lymphoblastic leukemia cells than other types of leukemias, non blood cancers, or normal cells and represents a lead molecule for developing antileukemic drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available